查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2083436

肺炎鏈球菌疫苗市場：2026-2032年全球市場預測（依疫苗類型、年齡層、給藥途徑、最終用戶和分銷管道分類）

Pneumococcal Vaccine Market by Vaccine Type, Age Group, Route of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，肺炎鏈球菌疫苗市場規模將達到 216.7 億美元，年複合成長率為 8.18%。

主要市場統計數據
基準年 2025 124.9億美元
預計年份：2026年 134.5億美元
預測年份 2032 216.7億美元
複合年成長率 (%) 8.18%

肺炎鏈球菌疫苗市場執行摘要

肺炎鏈球菌疫苗仍然是公共衛生和生命科學領域的重中之重，因為肺炎鏈球菌會引起兒童、成人和免疫力缺乏人群的侵襲性肺炎鏈球菌感染、肺炎、腦膜炎、菌血症和中耳炎。世界衛生組織（世衛組織）建議在兒童免疫規劃中接種肺炎球菌結合疫苗，而美國疾病管制與預防中心（疾管中心）則持續將肺炎球菌性肺炎列為成人住院的主要原因之一，也是老年人和患有基礎疾病人群重症疾病的主要原因。

肺炎鏈球菌疫苗領域的變革性變化

肺炎鏈球菌疫苗接種的格局正在從僅針對兒童的預防轉向終身免疫。雖然兒童計畫仍然是基礎，但由於人口老化、慢性病盛行率上升以及成人臨床風險增加，成人肺炎球菌疫苗的需求正在成長。廣譜結合疫苗透過針對更多致病性血清型，並在某些市場簡化接種程序，正在改變市場競爭格局。

人工智慧對肺炎鏈球菌疫苗的累積影響

人工智慧（AI）透過改善抗原選擇、血清型監測、臨床試驗設計、需求預測和生產品管，加速了肺炎球菌疫苗的研發和商業化。人工智慧驅動的基因組分析有助於監測肺炎球菌菌株的演變，並比傳統的人工方法更快地檢測血清型替換模式，從而加強疫苗更新和區域應對措施的基礎。

主要區域洞察：亞太地區、北美地區、拉丁美洲地區、歐洲地區、中東和非洲地區

亞太地區是重點關注區域，因為該地區出生人口眾多，成人疫苗接種意識不斷提高，而且中國、印度、日本、澳洲和韓國等國的政策正在現代化。由於各國免疫接種決策差異很大，因此本地血清型數據、定價、報銷方案設計以及生產夥伴關係對於市場准入至關重要。北美地區仍然是一個成熟且創新主導的地區，擁有美國疾病管制與預防中心 (CDC) 和北美免疫諮詢委員會 (NACI) 的指導、完善的藥房免疫接種基礎設施、電子免疫接種記錄以及高成本成人肺炎球菌疫苗的快速推廣。

關鍵區域洞察：東協、海灣合作理事會、歐盟、金磚國家、七國集團、北約

東協市場具有巨大的長期潛力，這得益於各國政府加強兒童免疫規劃、擴大私部門疫苗接種、改善疾病監測以及建構區域醫療衛生體系。然而，疫苗價格可負擔性、供應可預測性和低溫運輸穩定性仍然是關鍵挑戰。海灣合作理事會（GCC）正轉向預防性醫療保健策略，這為針對老年人、糖尿病患者、慢性呼吸系統和心血管疾病患者以及其他高危險群的成人肺炎球菌疫苗接種創造了機會。

對主要肺炎球菌疫苗市場關鍵國家的洞察

由於免疫實踐諮詢委員會 (ACIP) 的建議、零售藥局的廣泛供應、與聯邦醫療保險 (Medicare) 掛鉤的成人疫苗接種途徑以及完善的成人免疫基礎設施，美國是肺炎球菌疫苗的主要市場。另一方面，加拿大遵循加拿大免疫實踐諮詢委員會 (NACI) 的指南，其具體實施取決於各省和地區層面的計畫。墨西哥和巴西依靠大規模的公共免疫系統，尤其是巴西，透過國家計畫和本地生產體系支持疫苗的廣泛分發。在歐洲，英國、德國、法國、義大利和西班牙各自根據年齡、風險群、疫苗類型、報銷政策和公共衛生預算優先事項，實施不同的國家層級建議。同時，俄羅斯維持著大規模免疫環境。

為行業領導者提供的實用建議

產業領導者應優先考慮廣譜結合疫苗的策略、成人免疫接種的可靠證據，以及根據各國收入水平、免疫接種計劃、採購模式和政策環境量身定做的差異化市場進入方案。為了展現疫苗在兒童疾病預防之外的價值，必須投資於真實世界療效研究、血清型監測夥伴關係、藥物經濟模型以及上市後影響評估。

調查方法

本執行摘要基於來自權威公共衛生機構、監管機構、免疫諮詢機構、同行評審的臨床文獻以及疫苗市場政策資訊來源的二手研究。主要參考文獻包括世界衛生組織關於肺炎球菌疫苗的立場指導指南、美國疾病控制與預防中心和免疫實踐諮詢委員會的建議、美國國家免疫指南、國家免疫規劃、歐洲藥品管理局和其他監管信息，以及公開的採購和免疫規劃數據。

結論

肺炎鏈球菌疫苗市場正進入一個新階段，其特點是高成本的結合疫苗產品、成人接種範圍擴大、人工智慧驅動的監測以及更嚴格的報銷和公共採購證據要求。推動市場需求的因素包括肺炎球菌疾病持續帶來的疾病負擔、人口老化、基於風險的免疫接種政策以及全球減少抗生素使用和預防嚴重呼吸道感染疾病的迫切需求。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 肺炎鏈球菌疫苗市場：依疫苗類型分類

  • 結合疫苗
    • PCV13
    • PCV15
    • PCV20
  • 多醣體疫苗

第8章：肺炎鏈球菌疫苗市場：依年齡層別分類

  • 成人
  • 孩子們
  • 老年人

第9章：肺炎鏈球菌疫苗市場：依給藥途徑分類

  • 皮下
  • 肌肉內部

第10章 肺炎鏈球菌疫苗市場：依最終用戶分類

  • 門診部
  • 診所
  • 醫院
  • 疫苗接種中心

第11章 肺炎鏈球菌疫苗市場：依通路分類

  • 離線
  • 線上

第12章 肺炎鏈球菌疫苗市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 肺炎鏈球菌疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 肺炎鏈球菌疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Bharat Biotech International Ltd.
  • Biological E. Limited
  • BioNTech SE
  • GSK plc
  • Inventprise LLC
  • KM Biologics Co., Ltd.
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Pnuvax Incorporated
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • SK Bioscience Co., Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market is projected to grow by USD 21.67 billion at a CAGR of 8.18% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 12.49 billion
Estimated Year [2026] USD 13.45 billion
Forecast Year [2032] USD 21.67 billion
CAGR (%) 8.18%

Pneumococcal Vaccine Market Executive Summary

Pneumococcal vaccines remain a core public health and life sciences priority because Streptococcus pneumoniae causes invasive pneumococcal disease, pneumonia, meningitis, bacteremia, and otitis media across pediatric, adult, and immunocompromised populations. The World Health Organization recommends pneumococcal conjugate vaccines in childhood immunization programs, while the U.S. CDC continues to identify pneumococcal pneumonia as a major cause of adult hospitalization and severe disease among older adults and people with underlying medical conditions.

Market momentum is being shaped by broader-valent pneumococcal conjugate vaccines, adult immunization expansion, national immunization program updates, and rising attention to antimicrobial resistance. As countries evaluate PCV10, PCV13, PCV15, PCV20, PPSV23, and next-generation candidates, success increasingly depends on serotype coverage, real-world effectiveness, affordability, cold-chain execution, programmatic fit, and evidence-based policy adoption.

Transformative Shifts in the Pneumococcal Vaccine Landscape

The pneumococcal vaccine landscape is shifting from childhood-only protection toward life-course immunization. Pediatric programs remain foundational, but aging populations, chronic disease prevalence, and higher clinical risk among adults are elevating demand for adult pneumococcal vaccination. Broader-valent conjugate vaccines are changing competitive dynamics by targeting additional disease-causing serotypes and simplifying schedules in some markets.

Policy and procurement models are also evolving. High-income countries increasingly rely on advisory committee recommendations, real-world effectiveness data, pharmacoeconomic evidence, and post-authorization safety monitoring, while lower- and middle-income countries prioritize Gavi support, pooled procurement, supply reliability, and equitable access. At the same time, serotype replacement, antimicrobial resistance patterns, and regional differences in circulating strains are driving ongoing surveillance and vaccine portfolio diversification.

Cumulative Impact of Artificial Intelligence on Pneumococcal Vaccines

Artificial intelligence is accelerating pneumococcal vaccine development and commercialization by improving antigen selection, serotype surveillance, trial design, demand planning, and manufacturing quality control. AI-enabled genomic analytics can help monitor pneumococcal strain evolution and detect serotype replacement patterns faster than conventional manual approaches, strengthening evidence for vaccine updates and regional targeting.

Across commercialization and public health delivery, AI supports more accurate immunization demand planning, cold-chain risk prediction, adverse event signal detection, provider engagement, and prioritization of high-risk populations. For manufacturers, machine learning can improve yield monitoring, batch consistency, deviation detection, and process analytics in complex conjugate vaccine production. The cumulative impact is a more responsive pneumococcal vaccine ecosystem, though adoption must be governed by validated models, transparent data lineage, cybersecurity controls, privacy safeguards, and regulatory-grade documentation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is a high-priority region due to large birth cohorts, expanding adult vaccination awareness, and policy modernization in countries such as China, India, Japan, Australia, and South Korea. National immunization decisions vary widely, making local serotype data, pricing, reimbursement design, and manufacturing partnerships central to market access. North America remains a mature and innovation-led region, supported by CDC and NACI guidance, strong pharmacy vaccination infrastructure, electronic immunization records, and rapid adoption of higher-valent adult pneumococcal vaccines.

Latin America benefits from established public immunization systems and PAHO-supported procurement mechanisms, with Brazil and Mexico acting as important demand centers for routine pediatric protection and risk-based adult vaccination. Europe is shaped by national immunization technical advisory groups, EMA-authorized products, health technology assessment, and differentiated adult recommendations across countries. The Middle East, particularly GCC markets, is investing in preventive care and adult immunization as part of healthcare modernization, while Africa remains heavily influenced by donor-supported pediatric vaccine access, cold-chain capacity, health workforce reach, and the need to reduce pneumonia mortality through sustained routine immunization coverage.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets present strong long-term potential as governments strengthen childhood immunization, expand private-sector vaccination, improve disease surveillance, and build regional healthcare capacity; however, affordability, procurement predictability, and cold-chain consistency remain critical. The GCC is moving toward prevention-focused healthcare strategies, creating opportunities for adult pneumococcal vaccination among older adults, people with diabetes, people with chronic respiratory or cardiovascular disease, and other high-risk groups.

The European Union offers a regulated, evidence-driven environment where health technology assessment, budget impact, pharmacovigilance, and serotype epidemiology influence adoption. BRICS countries represent scale and manufacturing opportunity, especially as China, India, and Brazil invest in domestic vaccine capabilities, public-sector immunization reach, and localized regulatory pathways. G7 markets remain primary centers for higher-valent vaccine uptake, real-world evidence generation, adult immunization policy development, and premium access pathways. NATO countries overlap significantly with high-income immunization systems, where pandemic preparedness, resilient supply chains, life-course vaccination, and adult vaccination infrastructure are increasingly strategic priorities.

Key Country Insights Across Major Pneumococcal Vaccine Markets

The United States is a leading pneumococcal vaccine market due to ACIP recommendations, broad retail pharmacy access, Medicare-linked adult vaccination pathways, and strong adult immunization infrastructure, while Canada follows NACI guidance with implementation shaped by provincial and territorial programs. Mexico and Brazil rely on large public immunization systems, with Brazil's national program and local production ecosystem supporting broad reach. In Europe, the United Kingdom, Germany, France, Italy, and Spain each apply national recommendations that differ by age, risk group, vaccine type, reimbursement approach, and public health budget priorities, while Russia maintains a sizeable immunization environment influenced by domestic policy, epidemiological priorities, and supply considerations.

China is expanding its vaccine ecosystem through growing private demand, regulatory modernization, adult prevention awareness, and domestic innovation, while India combines a large pediatric population with public-sector introduction, affordability requirements, and expanding immunization infrastructure. Japan has well-established elderly vaccination policies and a strong preventive healthcare culture, Australia maintains evidence-based national immunization scheduling and high-quality surveillance systems, and South Korea supports advanced vaccine access through strong healthcare infrastructure, high awareness of adult preventive care, and robust clinical adoption pathways.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize broader-valent conjugate vaccine strategies, robust adult immunization evidence, and differentiated market access plans by country income level, immunization schedule, procurement model, and policy environment. Investment in real-world effectiveness studies, serotype surveillance partnerships, pharmacoeconomic modeling, and post-introduction impact assessments will be essential to demonstrate value beyond pediatric disease prevention.

Manufacturers should strengthen supply resilience through diversified antigen sourcing, scalable conjugation capacity, cold-chain optimization, regional fill-finish partnerships, and quality-by-design manufacturing systems. Commercial and medical teams should align messaging with public health priorities, including antimicrobial resistance reduction, hospital burden mitigation, protection of high-risk adults, and improved routine immunization coverage. AI should be deployed in validated use cases such as demand forecasting, pharmacovigilance, genomic surveillance, and manufacturing analytics, with governance frameworks that meet regulatory, ethical, privacy, and cybersecurity expectations.

Research Methodology

This executive summary is built on secondary research from recognized public health authorities, regulatory agencies, immunization advisory bodies, peer-reviewed clinical literature, and market-facing vaccine policy sources. Core references include WHO pneumococcal vaccine position guidance, CDC and ACIP recommendations, NACI guidance, national immunization schedules, EMA and other regulatory information, and publicly available procurement and immunization program data.

The methodology emphasizes triangulation across epidemiology, vaccine technology, regulatory approvals, reimbursement pathways, public procurement models, adult immunization policy, pediatric schedule adoption, pharmacovigilance, and regional immunization infrastructure. Insights are validated through consistency checks across authoritative sources and are interpreted to support strategic decision-making without relying on unverified market-size, market-share, or forecasting claims.

Conclusion

The pneumococcal vaccine market is entering a new phase defined by higher-valent conjugate products, expanded adult vaccination, AI-enabled surveillance, and stronger evidence requirements for reimbursement and public procurement. Demand is supported by persistent pneumococcal disease burden, aging populations, risk-based vaccination policies, and the global need to reduce antibiotic use and prevent severe respiratory infections.

Organizations that combine scientific differentiation, reliable supply, country-specific access strategies, credible real-world evidence, and strong public health partnerships will be best positioned to capture growth opportunities. The most competitive participants will treat pneumococcal vaccination not only as a pediatric public health intervention but as a life-course prevention platform with measurable clinical, operational, and economic value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pneumococcal Vaccine Market, by Vaccine Type

  • 7.1. Conjugate Vaccine
    • 7.1.1. Pcv13
    • 7.1.2. Pcv15
    • 7.1.3. Pcv20
  • 7.2. Polysaccharide Vaccine

8. Pneumococcal Vaccine Market, by Age Group

  • 8.1. Adult
  • 8.2. Children
  • 8.3. Geriatric

9. Pneumococcal Vaccine Market, by Route of Administration

  • 9.1. Subcutaneous
  • 9.2. Intramuscular

10. Pneumococcal Vaccine Market, by End User

  • 10.1. Ambulatory Care Centers
  • 10.2. Clinics
  • 10.3. Hospitals
  • 10.4. Immunization Centers

11. Pneumococcal Vaccine Market, by Distribution Channel

  • 11.1. Offline
  • 11.2. Online

12. Pneumococcal Vaccine Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Pneumococcal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Pneumococcal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Astellas Pharma Inc.
  • 16.3. Beijing Minhai Biotechnology Co., Ltd.
  • 16.4. Bharat Biotech International Ltd.
  • 16.5. Biological E. Limited
  • 16.6. BioNTech SE
  • 16.7. GSK plc
  • 16.8. Inventprise LLC
  • 16.9. KM Biologics Co., Ltd.
  • 16.10. LG Chem Ltd.
  • 16.11. Merck & Co., Inc.
  • 16.12. Novartis AG
  • 16.13. Panacea Biotec Ltd.
  • 16.14. Pfizer Inc.
  • 16.15. Pnuvax Incorporated
  • 16.16. Sanofi S.A.
  • 16.17. Serum Institute of India Pvt. Ltd.
  • 16.18. Shenzhen Kangtai Biological Products Co., Ltd.
  • 16.19. SK Bioscience Co., Ltd.
  • 16.20. Vaxcyte Inc.
  • 16.21. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CONJUGATE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PCV13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PCV13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PCV13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PCV15 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PCV15 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PCV15 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PCV20 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PCV20 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PCV20 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POLYSACCHARIDE VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ADULT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ADULT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ADULT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL GERIATRIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GERIATRIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GERIATRIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SUBCUTANEOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SUBCUTANEOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SUBCUTANEOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INTRAMUSCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INTRAMUSCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INTRAMUSCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AMBULATORY CARE CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 87. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 92. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 94. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. ASEAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 107. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 109. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GCC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPEAN UNION PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 123. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 128. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 130. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. G7 PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 135. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 137. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 139. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. NATO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 150. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 152. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 157. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 159. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 166. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 180. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 181. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 184. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 187. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 189. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 192. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 194. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 201. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 203. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 208. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 209. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 210. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 222. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 223. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 233. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 234. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 236. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 237. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 238. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 241. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINE, 2018-2032 (USD MILLION)
  • TABLE 243. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 244. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 245. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)